XM non fornisce servizi ai residenti degli Stati Uniti d'America.

XM non fornisce servizi ai residenti degli Stati Uniti d'America.
R
R

Roche

News

Reuters - 3 ore fa

Nykode Therapeutics To Regain Control Of VB10.Neo Program

BRIEF-Nykode Therapeutics To Regain Control Of VB10.Neo Program Nov 7 (Reuters) - Nykode Therapeutics ASA NYKD.OL : NYKODE THERAPEUTICS TO REGAIN CONTROL OF VB10.NEO PROGRAM NYKODE THERAPEUTICS ASA - IS NOT REQUIRED TO REFUND ANY UPFRONT PAYMENTS OR MAKE ANY FUTURE PAYMENTS TO GENENTECH ON TERMINATION NYKODE THERAPEUTICS ASA - EXISTING COLLABORATIO
R
Reuters - 6 giorni fa

Brainy efforts underway, but still some way to go for neuro drug developers

LIVE MARKETS-Brainy efforts underway, but still some way to go for neuro drug developers Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3% Cons Disc leads S&P sector gainers; Utilities sole loser Euro STOXX 600 index up 1.3% Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4% U.S. 10-Year Treasury yield edges up to ~4.33% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
B
R
U
U
Reuters - 1 settimana fa

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S
Reuters - 1 settimana fa

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S
Reuters - 1 settimana fa

Roche Presents New Data On Elecsys Amyloid Plasma Panel And Elecsys Ptau181

BRIEF-Roche Presents New Data On Elecsys Amyloid Plasma Panel And Elecsys Ptau181 Oct 31 (Reuters) - ROCHE HOLDING AG ROG.S : PRESENTS NEW DATA AT CTAD, DEMONSTRATING ITS GROWING MOMENTUM IN DIAGNOSTICS FOR ALZHEIMER'S DISEASE NEW DATA HIGHLIGHT POTENTIAL OF ROCHE ELECSYS® AMYLOID PLASMA PANEL AND ELECSYS PTAU181 FOR RULING OUT ALZHEIMER'S DISEASE
R
Reuters - 1 settimana fa

New England Journal Of Medicine Publishes Results For Roche's Itovebi, Showing More Than Doubling Of Progression-Free Survival In Certain Type Of Hr-Positive Advanced Breast Cancer

BRIEF-New England Journal Of Medicine Publishes Results For Roche's Itovebi, Showing More Than Doubling Of Progression-Free Survival In Certain Type Of Hr-Positive Advanced Breast Cancer Oct 31 (Reuters) - Roche Holding AG ROG.S : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES LANDMARK PHASE III RESULTS FOR ROCHE’S ITOVEBI, SHOWING MORE THAN DOUBLING OF PROGRESSION-FREE SURVIVAL IN CERTAIN TYPE OF HR-POSITIVE ADVANCED BREAST CANCER U.S.
R
Reuters - 1 settimana fa

Nikkei closes at 2-week peak as tech shares track Nasdaq higher

Nikkei closes at 2-week peak as tech shares track Nasdaq higher Updates at 0600 GMT TOKYO, Oct 30 (Reuters) - Japan's Nikkei share average rose to a two-week closing high on Wednesday, as technology stocks tracked the Nasdaq's record finish overnight. The Nikkei .N225 climbed 0.96% to 39,277.39, its highest close since Oct. 15 in its third straight session of gains.
G
R
U
J
U
U
Reuters - 1 settimana fa

Japan's Nikkei hits two-week high as tech shares track Nasdaq's record high

Japan's Nikkei hits two-week high as tech shares track Nasdaq's record high TOKYO, Oct 30 (Reuters) - Japan's Nikkei share average touched a two-week high on Wednesday, as technology stocks tracked Nasdaq's record closing high overnight. The Nikkei .N225 was up 1.25% at 39,390.49 by the midday break, its highest level since Oct. 15. The broader Topix .TOPX rose 1.13% to 2,712.26. "There were not any strong market-moving cues and the momentum is not strong," said Fumio Matsumoto, chief strategist
G
N
R
U
J
U
U
Reuters - 1 settimana fa

NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir

BRIEF-NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir Oct 28 (Reuters) - NIH: NIH: BOVINE H5N1 INFLUENZA FROM INFECTED WORKER TRANSMISSIBLE AND LETHAL IN ANIMAL MODELS NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS SUSCEPTIBLE TO ANTIVIRAL XOFLUZA AND NEURAMINIDASE INHIBITOR ZANAMIVIR NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS LESS S
G
R
Reuters - 2 settimane fa

Assa Abloy, Kering, L'Oréal

EUROPE RESEARCH ROUNDUP-Assa Abloy, Kering, L'Oréal Oct 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Assa Abloy, Kering and L'Oréal, on Thursday. HIGHLIGHTS * Assa Abloy ASSAb.ST : Deutsche Bank raises target price to SEK 305 from SEK 300 * Barratt Redrow Plc BTRW.L : Morgan Stanley cuts target price to 580p from 600p * Dowlais Group Plc DWL.L : Citigroup raises to neutral from sell * Kering PRTP.PA : JP Morgan cuts target
B
D
D
D
E
E
H
H
K
K
L
L
P
R
R
R
S
S
S
S
S
T
Z
A
A
A
A
A
E
S
Reuters - 2 settimane fa

Roche comes out against allowing takeover of drug manufacturer Catalent

UPDATE 5-Roche comes out against allowing takeover of drug manufacturer Catalent Adds comment from Novo Holdings in paragraph 13 Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy groups also voice concerns over the deal Novo Nordisk and Catalent defend the acquisition, citing ample competition By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of p
A
A
P
R
Reuters - 2 settimane fa

Europe struggles for direction, earnings mixed

LIVE MARKETS-Europe struggles for direction, earnings mixed STOXX 600 flat Deutsche Bank, L'Oreal fall after earnings Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE STRUGGLES FOR DIRECTION, EARNINGS MIXED European equities are mixed on Wednesday, after several corporate reports, with markets remaining on edge as the U.S.
D
I
L
L
R
S
V
S
E
F
U
G
Reuters - 2 settimane fa

Roche CEO comes out against approving takeover of drug manufacturer Catalent

Roche CEO comes out against approving takeover of drug manufacturer Catalent FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss pharmaceuticals giant Roche ROG.S said competition authorities should not allow the controlling shareholder of Novo Nordisk NOVOb.CO to acquiring contract drug manufacturer Catalent CTLT.N . "It's not a problem for us, but it could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available.
R
Reuters - 2 settimane fa

Europe before the bell: futures dip after raft of earnings

LIVE MARKETS-Europe before the bell: futures dip after raft of earnings Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: FUTURES DIP AFTER RAFT OF EARNINGS European stock futures are edging lower in early trade after a large number of corporate earnings, with markets also watching rising yields and preparing for the upcoming U.S.
D
I
L
P
R
V
E
F
U
G
Reuters - 2 settimane fa

Roche CEO says more people have mpox in Europe than has been reported

UPDATE 1-Roche CEO says more people have mpox in Europe than has been reported Adds production capacity detail, background on mpox spread By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of Roche ROG.S said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the Swiss group could quickly offer 10 times more test kits than are currently in demand.
R
Reuters - 2 settimane fa

Roche seen rising after Q3 sales beat

BUZZ-Roche seen rising after Q3 sales beat ** Shares in Roche ROG.S are indicated up 1.1% in Julius Baer premarket trade after the Swiss drugmaker reports better-than-expected Q3 sales ** "Reported 3Q24 Group sales beats consensus and our expectations," Vontobel says ** Key growth drivers such as multiple sclerosis drug Ocrevus, haemophilia shot Hemlibra and recently launched eye drug Vabysmo continue to perform above expectations, the brokerage highlights ** Analysts at J.P.
R
J
Reuters - 2 settimane fa

Roche CEO says more mpox cases likely to be reported in Europe

Roche CEO says more mpox cases likely to be reported in Europe FRANKFURT, Oct 23 (Reuters) - The CEO of Roche ROG.S said more cases of mpox infection have likely occurred in Europe than previously reported and that the group could quickly offer 10 times more test kits than are currently in demand. "It seems like there are more mpox cases already in Europe, maybe not all of them are in the media yet," CEO Thomas Schinecker said in a media call after the Swiss drugs and diagnostics company reporte
R
Reuters - 2 settimane fa

Roche Q3 sales advance by forex-adj 9%, beating market view

UPDATE 1-Roche Q3 sales advance by forex-adj 9%, beating market view Adds details on drugs, full-year guidance By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - Roche 's ROG.S third-quarter sales gained a currency-adjusted 9% , beating market expectations, on higher prescriptions of once-monthly haemophilia shot Hemlibra and recently launched eye drug Vabysmo.
R
Reuters - 2 settimane fa

Roche Q3 sales advance by forex-adj 9%, beating market view

Roche Q3 sales advance by forex-adj 9%, beating market view FRANKFURT, Oct 23 (Reuters) - Roche ROG.S on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion). That surpassed an analysts' consensus estimate of 14.9 billion francs, based on LSEG data. ($1 = 0.8671 Swiss francs) Reporting
R
Reuters - 3 settimane fa

FDA approves Astellas' gastric cancer therapy

UPDATE 4-FDA approves Astellas' gastric cancer therapy Adds pricing and availability in paragraph 4 By Sriparna Roy Oct 18 (Reuters) - The U.S. Food and Drug Administration approved Astellas' 4503.T therapy to treat a type of gastric cancer, the health regulator's website showed on Friday. The therapy, branded as Vyloy, was approved to be used in combination with a type of chemotherapy for patients with a type of cancer which begins in the gastroesophageal junction, where the esophagus and stoma
A
R

Condizioni

Asset popolari

Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.

Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.

Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.

Avvertenza sul rischio: Il tuo capitale è a rischio. I prodotti con leva finanziaria possono non essere adatti a tutti. Ti chiediamo di consultare attentamente la nostra Informativa sul rischio.